Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

419
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

362
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
362
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

336
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

564
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
564
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

79
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
79
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mineralocorticoid Antagonists for Post-MI HFpEF: Plausible Biology Meets Low Residual Risk?

The American journal of medicine·2026
Same author

The Role of Implicit Bias in Shaping Medication Prescribing Practices: A Scoping Review.

Journal of the American College of Clinical Pharmacy : JACCP·2026
Same author

Heart Failure Duration, Cardiac Remodeling, Dysfunction, and Hemodynamic Severity in HFpEF and HFmrEF: Insights From REDUCE LAP-HF II.

JACC. Heart failure·2026
Same author

The impact of data source on real-world medication adherence and exposure measures: From prescription to sold.

Journal of managed care & specialty pharmacy·2026
Same author

Rapid quantitative urinary chloride sensing with conductivity correction for cardiac patient management.

Biosensors & bioelectronics·2026
Same author

Patient and Clinician Attitudes Toward Mobile Health Apps: Qualitative Study.

JMIR mHealth and uHealth·2026
Same journal

Achieving Equity in Generative Artificial Intelligence in Cardiovascular Medicine.

JACC. Advances·2026
Same journal

Real-World Experience With a Novel Intravascular Hertz Contact Lithotripsy Balloon in Severely Calcified Coronary Lesions.

JACC. Advances·2026
Same journal

Trends in Cardiac Arrest Mortality Among Young Adults in the United States, 1999 to 2024.

JACC. Advances·2026
Same journal

Pulmonary Hypertension in Adults With a Systemic Right Ventricle (Biventricular Circulation).

JACC. Advances·2026
Same journal

Cholesterol Perceptions and Preferences Among Young Adults: A Survey of U.S. Adults Aged 30 to 39 Years.

JACC. Advances·2026
Same journal

Radiomics for the Detection and Prediction of Cancer Therapy-Related Cardiotoxicity.

JACC. Advances·2026
See all related articles

Related Experiment Video

Updated: Jun 22, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.4K

A Computable Algorithm for Medication Optimization in Heart Failure With Reduced Ejection Fraction.

Michael P Dorsch1,2, Aaron Sifuentes3, David J Cordwin1

  • 1Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA.

JACC. Advances
|June 28, 2024
PubMed
Summary
This summary is machine-generated.

A new algorithm can optimize guideline-directed medical therapy (GDMT) for heart failure patients. Higher medication optimization scores (MOS) were linked to better clinical outcomes, suggesting potential for improved heart failure care.

Keywords:
computable knowledgedigital healthhealth technologyheart failurequality and outcomesstatements and guidelines

More Related Videos

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

760
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

1.8K

Related Experiment Videos

Last Updated: Jun 22, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.4K
Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

760
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

1.8K

Area of Science:

  • Cardiology
  • Medical Informatics
  • Clinical Trials

Background:

  • Optimizing guideline-directed medical therapy (GDMT) is crucial for improving outcomes in patients with heart failure with reduced ejection fraction (HFrEF).
  • Suboptimal GDMT is a common challenge in clinical practice, even within structured clinical trials.

Purpose of the Study:

  • To evaluate a novel computable algorithm designed to recommend GDMT for HFrEF.
  • To assess if the algorithm's recommendations align with actual medication adjustments and if its output correlates with patient outcomes.

Main Methods:

  • Utilized clinical trial data from GUIDE-IT and HF-ACTION studies.
  • Applied a computable medication optimization algorithm to generate GDMT recommendations and a medication optimization score (MOS).
  • Compared algorithm-based recommendations to actual medication changes and analyzed the association between MOS and clinical endpoints using Cox proportional-hazards models.

Main Results:

  • The algorithm identified significant opportunities for initiating and titrating GDMT (ACEI/ARB, beta-blockers, MRAs) that were underutilized in the trials.
  • A higher baseline MOS was significantly associated with a reduced risk of cardiovascular death or heart failure hospitalization in GUIDE-IT (HR: 0.41) and all-cause death/hospitalization in HF-ACTION (HR: 0.61).
  • The algorithm demonstrated accuracy in identifying patients who could benefit from GDMT optimization.

Conclusions:

  • The computable algorithm effectively identifies patients requiring GDMT optimization in HFrEF.
  • The algorithm-generated MOS is a predictor of improved clinical outcomes, highlighting its potential clinical utility.
  • Implementation of this algorithm in clinical settings could address suboptimal GDMT and improve care for HFrEF patients.